Celesio announces agreement to acquire Bupa Home Healthcare

Celesio, a leading healthcare services company, has today announced an agreement with Bupa to purchase Bupa Home Healthcare, a clinical homecare provider.

The acquisition, which is subject to regulatory approval, will see Celesio expand its home healthcare expertise and capabilities. The addition of Bupa Home Healthcare to Celesio UK will complement existing services and strengthen the company’s national healthcare infrastructure, enabling patients to benefit from greater flexibility and more choice.

Marc Owen, Chairman of the Management Board of Celesio Group, said: “We are delighted to make this announcement and look forward to welcoming our new colleagues to the Celesio family. Bupa Home Healthcare is an excellent addition to our business as we share the same values, where patients come first, and we both strive to help patients live more fulfilling lives.

“As the population continues to age and the number of people requiring speciality medicines increases it is vital we invest in home healthcare solutions to help the NHS meet demand both now and in the future. Bupa Home Healthcare joining the Celesio family will enable us to enhance our clinical homecare offering and provide a broader set of services.

Richard Bowden, Bupa UK Managing Director, said: “Bupa Home Healthcare is a great fit for Celesio which has a long term commitment to clinical home healthcare and shares our dedication to patients, customers and employees and focus on delivering high quality care.”

Bupa Home Healthcare was acquired by Bupa UK in 2006 and has grown substantially over recent years, treating over 35,000 patients a year in their own homes.

Bupa Home Healthcare provides clinical care in patients’ homes for a number of conditions including those that require speciality medicines such as Intestinal Failure, Lysosomal Storage Disorder, Cancer, Multiple Sclerosis and Rheumatoid Arthritis. The company has a national nursing team and its own aseptic manufacturing facilities. Around 1,000 employees are based across the UK.

Once the deal is complete the company will continue to operate from the same offices and patients and customers will receive the same high quality service from the same dedicated teams.

The deal will complete following regulatory approval.